Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Indivior PLC
  6. Summary
    INDV   GB00BRS65X63

INDIVIOR PLC

(INDV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
158(c) 155.9(c) 154.4(c) 155(c) 153.1(c) Last
472 739 2 393 173 1 190 678 934 824 3 133 520 Volume
+0.13% -1.33% -0.96% +0.39% -1.23% Change
More quotes
Financials (USD)
Sales 2021 665 M - -
Net income 2021 128 M - -
Net cash position 2021 644 M - -
P/E ratio 2021 11,7x
Yield 2021 -
Sales 2022 739 M - -
Net income 2022 150 M - -
Net cash position 2022 699 M - -
P/E ratio 2022 9,19x
Yield 2022 -
Capitalization 1 552 M 1 552 M -
EV / Sales 2021 1,37x
EV / Sales 2022 1,16x
Nbr of Employees 788
Free-Float 98,7%
More Financials
Company
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film... 
Sector
Pharmaceuticals
Calendar
07/29Earnings Release
More about the company
Ratings of Indivior PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about INDIVIOR PLC
06/17PRESS RELEASEá : Addex Shareholders Approve All Resolutions at Annual General Me..
DJ
06/08Indivior looks beyond opioid addiction with foray into cannabis disorder trea..
RE
06/08INDIVIORá : Extends Leadership Position in Substance Use Disorder Treatment with..
PU
06/07PRESS RELEASE : Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
DJ
06/03INDIVIORá : Panel Discussion Among Government Lawyers Provides Key Insights Into..
AQ
05/24PRESS RELEASE : Addex to Participate at the Benchmark Company Healthcare House C..
DJ
05/17PRESS RELEASE : Addex's Dipraglurant Restores Synaptic Plasticity in Models of D..
DJ
05/14PRESS RELEASE : Addex Convenes Annual General Meeting 2021
DJ
05/05PRESS RELEASE : Addex Reports Q1 2021 Financial Results and Provides Corporate U..
DJ
05/03PRESS RELEASE : Addex Therapeutics to Release Q1 2021 Financial Results and Host..
DJ
04/30INDIVIORá : Applauds Biden Administration's New Buprenorphine Practice Guideline..
PU
04/29INDIVIORá : 2021 First Quarter Results Presentation
PU
04/29INDIVIORá : Turns To Q1 Net Income On Solid Product Growth
MT
04/29INDIVIORá : Announces Q1 2021 Financial Results
PU
04/28INDIVIORá : Statement Regarding State Attorney General's Recent Announcements Re..
PU
More news
News in other languages on INDIVIOR PLC
05/05Addex a étoffé sa trésorerie au premier trimestre
03/11Addex prévoit de rattraper le retard accumulé en 2020
01/26STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
2020Addex dämmt Verlust im Q3 ein - Pipeline-Verzögerungen wegen Covid-19
2020Aktien Schweiz Schluss: SMI fester zum Wochenstart - Finanzwerte legen zu
More news
Analyst Recommendations on INDIVIOR PLC
More recommendations
Stock Trading Strategies
INDIVIOR PLC - 05/14
Towards the breakout of a major resistance level
BUY
More Stock Trading Analysis
Chart INDIVIOR PLC
Duration : Period :
Indivior PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 3,36 $
Last Close Price 2,11 $
Spread / Highest target 114%
Spread / Average Target 59,1%
Spread / Lowest Target 25,4%
EPS Revisions
Managers and Directors
NameTitle
Mark Crossley Executive Director, CEO & COO
Ryan Preblick Chief Financial Officer & Executive Director
Graham C. Hetherington Chairman
Christian Heidbreder Chief Scientific Officer
Murali Gopal Chief Medical Officer
Sector and Competitors